Article Text

PDF

P5.009 Performance of Cervical Cancer Screening Tests in HIV Positive Women in Africa: Influence of CD4 Counts
  1. S Delany1,
  2. H A Weiss2,
  3. O Lompo3,
  4. S Doutre4,
  5. T Omar1,
  6. H Kelly2,
  7. S Zan3,
  8. P Michelow1,
  9. V Costes4,
  10. P Mayaud2
  1. 1Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
  2. 2London School of Hygiene & Tropical Medicine, London, UK
  3. 3Centre de Recherche Internationale sur la Sante, Ouagadougou, Burkina Faso
  4. 4University of Montpellier 1 & INSERM U1058, Montpellier, France

Abstract

Background To evaluate strategies for cervical cancer screening among HIV-positive African women, against histological CIN endpoints.

Abstract P5.009 Table 1

Prevalence of CIN2+, and performance of screening tests singly or in combination by CD4+ count among HIV-positive women in Burkina Faso and South Africa

MethodsThe HARP study enrolled HIV-positive women aged 25–50 in Burkina Faso (BF) and South Africa (SA). A stratified sampling strategy was used, with 2/3 of women on ART. Three cervical cancer screening methods were evaluated; (1) visual inspection (VIA/VILI); (2) high-risk HPV DNA (HC-2); (3) conventional cytology. Four-quadrant cervical biopsies were obtained among women with abnormalities detected by at least one test or by colposcopy.

Results 1252 women were enrolled (628 in BF; 624 in SA). The distribution of CD4 count (cells/µL) was similar in both sites: 68% with CD4+ ≥ 350 and 10% with CD4 < 200. Prevalence of high risk (HR)-HPV was 43% in BF and 61% in SA, and decreased with increasing CD4+ count (P-trend < 0.001). VIA/VILI positivity was 24% in BF and 41% in SA (P < 0.001) but did not vary by CD4 count (P-trend = 0.30). Prevalence of abnormal cytology (≥LSIL & ≥HSIL) was higher in SA (89% & 30%) than in BF (24% & 5%). 62% and 97% women were biopsied in BF and SA respectively, with CIN2+ prevalence of 6% and 29%, respectively (155 of 949 evaluated women thus far). CIN2+ prevalence decreased with increasing CD4+ (Table). Sensitivity of the single screening methods to detect CIN-2 decreased with increasing CD4+ count, whilst specificity tended to increase with increased CD4+ count (Table). Overall, HR-HPV DNA was the most sensitive test (94%) and HSIL+ cytology the most specific (90%). Further analyses with combination of tests did not show much improvement on performance.

Conclusions Cervical cancer screening tests among HIV-positive women are most sensitive among women with CD4+ count below 200 cells/µL. Screening strategies may vary according to CD4+ count but this will need to be evaluated prospectively.

  • cervical cancer
  • HIV
  • screening

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.